MEI Pharma, Inc.
(NASDAQ : MEIP)

( )
MEIP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. 0.00%29.0714.1%$171.05m
ICLRICON plc 0.00%229.204.2%$156.70m
JAZZJazz Pharmaceuticals Plc 0.00%179.172.2%$142.15m
HZNPHorizon Therapeutics Plc 0.00%92.145.5%$124.53m
CTLTCatalent, Inc. -0.03%102.672.1%$105.63m
BHCBausch Health Cos., Inc. 0.00%29.070.0%$91.68m
SAVACassava Sciences, Inc. 0.00%40.920.0%$55.78m
UTHRUnited Therapeutics Corp. 0.00%197.8714.0%$55.65m
PRGOPerrigo Co. Plc -0.09%45.826.9%$49.71m
BLRXBioLineRx Ltd. 1.40%2.890.8%$39.51m
ARGXargenx SE 0.00%272.300.0%$38.23m
SAGESAGE Therapeutics, Inc. 0.00%70.867.6%$33.60m
PCRXPacira Biosciences, Inc. 0.00%62.219.9%$30.64m
AXSMAxsome Therapeutics, Inc. 0.00%58.421.9%$26.79m
RVMDRevolution Medicines, Inc. 0.00%31.990.0%$23.38m

Company Profile

MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.